Japanese clinical medicine最新文献_第5页

Explanation of the insulin paradox from the evolutionary point of view. 从进化的角度解释胰岛素悖论。

Japanese clinical medicine Pub Date : 2012-09-17 eCollection Date: 2012-01-01 DOI: 10.4137/JCM.S10274

Hiroyuki Koshiyama

引用次数: 0

Estimation of Duration of Symptoms in Fulminant Type 1 Diabetes Mellitus Using HbA1c or Glycated Albumin. 用HbA1c或糖化白蛋白评估暴发型1型糖尿病症状持续时间

Japanese clinical medicine Pub Date : 2012-05-21 eCollection Date: 2012-01-01 DOI: 10.4137/JCM.S9509

Akitsu Kawabe, Takashi Seta, Sumie Fujii, Masayo Yamada, Shogo Oki, Jun Murai, Hiroshi Saito, Masafumi Koga

引用次数: 1

Improvement of Quality of Life (QOL) in Osteoporotic Patients by Elcatonin Treatment: A Trial Taking the Participants' Preference into Account. Elcatonin治疗对骨质疏松患者生活质量(QOL)的改善:一项考虑受试者偏好的试验

Japanese clinical medicine Pub Date : 2012-04-18 eCollection Date: 2012-01-01 DOI: 10.4137/JCM.S8291

K Yoh, T Uzawa, T Orito, K Tanaka

{"title":"Improvement of Quality of Life (QOL) in Osteoporotic Patients by Elcatonin Treatment: A Trial Taking the Participants' Preference into Account.","authors":"K Yoh, T Uzawa, T Orito, K Tanaka","doi":"10.4137/JCM.S8291","DOIUrl":"https://doi.org/10.4137/JCM.S8291","url":null,"abstract":"Osteoporosis is associated with compromised quality of life (QOL), to which pain has the most important contribution. Elcatonin, a derivative of calcitonin, is widely used in the treatment of osteoporosis in two ways. One is as the inhibitor of osteoclastic bone resorption. The other is for osteoporosis-related pain based on the unique analgesic effects of elcatonin. Since pain is subjective in nature, and QOL is the only clinical outcome representing the patients' subjective perception of health status, pain associated with osteoporosis would be best evaluated based on QOL assessment. Evidence based medicine gives the highest remarks to the double-blinded, randomized controlled trial, which, however, cannot be free from methodological problems on some occasions. For example, it is practically impossible to remain blinded in the trial of a potent analgesia, which in turn causes biases. Thus, the significance of taking the patients' preference into account is increasingly acknowledged. In this study, 45 osteoporotic patients were given brochures describing the pros and cons on the three treatment choices; calcium and alfacalcidol, additional use of elcatonin, and additional use of bisphosphonate. Those who favored elcatonin were older, had more vertebral fractures, and lower QOL scores. QOL was evaluated before and three months after the treatment using SF-8; the most widely used generic questionnaire, and RDQ; a lumbago-specific measure. Elcatonin treatment improved physical function, general health, and vitality of SF-8, and RDQ score. Although this is a preliminary study, our results suggest that patients with vertebral fracture(s) have impaired QOL and more likely to favor elcatonin treatment expecting analgesia. ","PeriodicalId":89792,"journal":{"name":"Japanese clinical medicine","volume":"3 ","pages":"9-14"},"PeriodicalIF":0.0,"publicationDate":"2012-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/JCM.S8291","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31657878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus. 二肽基肽酶-4抑制剂、磺脲和二甲双胍联合治疗可显著改善日本2型糖尿病患者的HbA1c水平

Japanese clinical medicine Pub Date : 2012-02-16 eCollection Date: 2012-01-01 DOI: 10.4137/JCM.S8571

Koichi Hirao, Hajime Maeda, Shin-Ichiro Shirabe, Ritsuko Yamamoto, Tetsuyuki Hirao, Setsuko Hirao, Mikio Yamauchi, Keiko Arai

{"title":"Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.","authors":"Koichi Hirao, Hajime Maeda, Shin-Ichiro Shirabe, Ritsuko Yamamoto, Tetsuyuki Hirao, Setsuko Hirao, Mikio Yamauchi, Keiko Arai","doi":"10.4137/JCM.S8571","DOIUrl":"https://doi.org/10.4137/JCM.S8571","url":null,"abstract":"Combination therapy with a dipeptidyl peptidase (DPP)-4 inhibitor and metformin or sulfonylurea results in substantial and additive glucose-lowering effects in patients with type 2 diabetes mellitus (T2DM). However, it is not known whether triple combination therapy with a DPP-4 inhibitor, metformin, and sulfonylurea has greater additive effects or synergic effects. In the present report, we investigated the effect of addition of sitagliptin, the first-in-class DPP-4 inhibitor, to ongoing metformin and sulfonylurea therapy in three female Japanese patients with T2DM who refused insulin therapy. Combined treatment with all three drugs resulted in marked improvements in HbA1c. In the first patient, HbA1c levels decreased from 11.1% to 6.1% after the addition of sitagliptin to metformin 1000 mg, glibenclamide, and miglitol, even though the dose of glibenclamide was decreased. HbA1c levels decreased similarly in the second patient, who was being treated with metformin and glibenclamide, from 7.9% to 6.0% after addition of sitagliptin and an increase in metformin to 2250 mg; this patient ceased glibenclamide because of hypoglycemia and instead was started on low-dose glimepiride. In the third patient, HbA1c levels decreased from 8.6% to 7.1% after addition of glimepiride to ongoing sitagliptin and metformin therapy. All three patients had refused insulin therapy, despite the fact that ongoing combination therapy had failed to achieve satisfactory glycemic control. Based on these results, it is likely that the addition of sitagliptin to metformin and at least a small dose of sulfonylurea may be effective in reducing HbA1c levels without weight gain. This triple combination therapy may prove useful in at least some patients who need initiation of insulin therapy. ","PeriodicalId":89792,"journal":{"name":"Japanese clinical medicine","volume":"3 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2012-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/JCM.S8571","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31657877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Further possible mechanisms of dipeptidyl peptidase-4 inhibitors to decrease blood glucose in subjects with type 2 diabetes. 二肽基肽酶-4抑制剂降低2型糖尿病患者血糖的进一步可能机制

Japanese clinical medicine Pub Date : 2011-10-31 Print Date: 2011-01-01 DOI: 10.4137/JCM.S8408

Hiroyuki Koshiyama

引用次数: 1

Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study). 日本高甘油三酯血症患者在普通医疗实践下接受匹伐他汀治疗时，非诺贝特的额外治疗(APPROACH-J研究)。

Japanese clinical medicine Pub Date : 2011-09-19 Print Date: 2011-01-01 DOI: 10.4137/JCM.S7863

Yasushi Wakida, Satoshi Suzuki, Hirohiko Nomura, Tatsuya Isomura

{"title":"Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study).","authors":"Yasushi Wakida, Satoshi Suzuki, Hirohiko Nomura, Tatsuya Isomura","doi":"10.4137/JCM.S7863","DOIUrl":"https://doi.org/10.4137/JCM.S7863","url":null,"abstract":"Safety and efficacy of combination therapy of pitavastatin and fenofibrate were examined in consecutive case series with fasting serum triglycerides ≥ 150 mg/dL despite receiving pitavastatin 1 or 2 mg daily for over 2 months and additionally administered micronized fenofibrate 67 mg daily for another 4 to 16 weeks. Such low doses were selected in consideration of safety, and normal liver and renal functions were incorporated in inclusion criteria. In result, a total of 56 cases were examined. The addition of fenofibrate 67 mg to pitavastatin 1 mg/2 mg yielded a 36.8%/35.6% reduction in triglycerides and 6.4%/12.4% elevation in high-density lipoprotein cholesterol, respectively. Almost 70% of the patients achieved triglycerides <150 mg/dL. Statistically significant elevation and decrease were observed in high-density lipoprotein cholesterol level and low-density lipoprotein cholesterol, respectively. Laboratory tests for liver, renal and muscle function statistically significantly elevated after starting fenofibrate co-administration, which were considered comparable to the effect of fenofibrate alone. No myopathy or serious adverse events were reported. In conclusion, while the safety and tolerability need to be further examined over the longer term, and careful monitoring is still needed, this regimen could be considered as one of the treatment option for hypercholesterolemia associated with hypertriglyceridemia. ","PeriodicalId":89792,"journal":{"name":"Japanese clinical medicine","volume":"2 ","pages":"57-66"},"PeriodicalIF":0.0,"publicationDate":"2011-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/JCM.S7863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31247434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Introduction of new laryngeal closure methods for patients with intractable aspiration. 介绍治疗顽固性误吸的喉头闭合新方法。

Japanese clinical medicine Pub Date : 2011-09-04 Print Date: 2011-01-01 DOI: 10.4137/JCM.S7537

Masaru Tateda, Tetsuya Yokoyama, Atsuhiro Mizukawa, Hiroaki Sato

引用次数: 3

Time and Costs of Insulin Treatment in the Care of Newly Registered Type 2 Diabetes Patients in Diabetes Clinics Across Japan (JDDM 22). 日本糖尿病诊所新登记的2型糖尿病患者胰岛素治疗的时间和成本(JDDM 22)。

Japanese clinical medicine Pub Date : 2011-08-28 Print Date: 2011-01-01 DOI: 10.4137/JCM.S7736

Mariko Oishi, Hiroki Yokoyama, Nobuyuki Abe, Kouichi Iwasaki, Fuminobu Okuguchi, Koichi Kawai, Hidekatsu Sugimto, Hiroshi Takamura, Hiroshi Takeda, Kunihiro Doi, Kouichi Hirao, Shunya Ikeda

{"title":"Time and Costs of Insulin Treatment in the Care of Newly Registered Type 2 Diabetes Patients in Diabetes Clinics Across Japan (JDDM 22).","authors":"Mariko Oishi, Hiroki Yokoyama, Nobuyuki Abe, Kouichi Iwasaki, Fuminobu Okuguchi, Koichi Kawai, Hidekatsu Sugimto, Hiroshi Takamura, Hiroshi Takeda, Kunihiro Doi, Kouichi Hirao, Shunya Ikeda","doi":"10.4137/JCM.S7736","DOIUrl":"https://doi.org/10.4137/JCM.S7736","url":null,"abstract":"Aims: To study the time and costs of insulin treatment of newly registered outpatients with Type 2 diabetes mellitus (T2DM).Methods: In total, 355 patients with T2DM were registered on their first visit to one of 11 diabetes clinics across Japan. Of these, 313 were not being treated with insulin (the non-insulin group), whereas 42 were (the insulin group). In the insulin group, 26 were already on insulin at the first visit, whereas 16 were started on insulin after their first visit. The time and costs involved in the care were recorded over the following 5 months.Results: In the first 3 months, considerable time was expended in both groups, with the time spent by physicians a little (but significantly) longer for the insulin group. The total time expended by all care providers was approximately 1.3-fold greater for the insulin compared with the non-insulin group. The total cost and total cost/min for the insulin group was almost twice that for the non-insulin group. Over the 5-month period, mean HbA1c in the non-insulin group improved from 8.0% to 6.5%, with 72% achieving a glycemic target of HbA1c ≤ 6.5%. In contrast, in the insulin group, mean HbA1c improved from 9.4% to 7.6%, with only 39% achieving the target. There were no reports of major hypoglycemic events in either group and body mass index remained stable.Conclusions: The insulin therapy for T2DM can be achieved safely and effectively at outpatient clinics, even though it requires considerably more time and resources than non-insulin therapy.","PeriodicalId":89792,"journal":{"name":"Japanese clinical medicine","volume":"2 ","pages":"43-51"},"PeriodicalIF":0.0,"publicationDate":"2011-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/JCM.S7736","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31247432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of Autoantibodies for α and γ-Enolase in Serum from a Patient with Melanoma. 黑色素瘤患者血清α和γ烯醇化酶自身抗体的鉴定。

Japanese clinical medicine Pub Date : 2011-07-17 Print Date: 2011-01-01 DOI: 10.4137/JCM.S6256

Yui Hiura, Toyofumi Nakanishi, Miki Tanioka, Takayuki Takubo, Shinichi Moriwaki

引用次数: 3

Ultrasound guided obturator versus sciatic nerve block in addition to continuous femoral nerve block for analgesia after total knee arthroplasty. 超声引导下闭孔神经阻滞与坐骨神经阻滞联合连续股神经阻滞用于全膝关节置换术后镇痛。

Japanese clinical medicine Pub Date : 2011-07-11 Print Date: 2011-01-01 DOI: 10.4137/JCM.S7399

Keita Sato, Seijyu Sai, Naoto Shirai, Takehiko Adachi

引用次数: 17